Treatment of severe diarrhea caused by Cryptosporidium parvum with oral bovine immunoglobulin concentrate in patients with AIDS
We prospectively evaluated the safety and efficacy of colostrum-derived bovine immunoglobulin concentrate in the treatment of diarrhea caused by Cryptosporidium parvum in patients with AIDS. A total of 24 patients with severe chronic diarrhea and AIDS were stratified to one of three cohorts: (1) C....
Gespeichert in:
| Veröffentlicht in: | Journal of acquired immune deficiency syndromes and human retrovirology 1996-12, Vol.13 (4), p.348-354 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 354 |
|---|---|
| container_issue | 4 |
| container_start_page | 348 |
| container_title | Journal of acquired immune deficiency syndromes and human retrovirology |
| container_volume | 13 |
| creator | GREENBERG, P. D CELLO, J. P |
| description | We prospectively evaluated the safety and efficacy of colostrum-derived bovine immunoglobulin concentrate in the treatment of diarrhea caused by Cryptosporidium parvum in patients with AIDS. A total of 24 patients with severe chronic diarrhea and AIDS were stratified to one of three cohorts: (1) C. parvum infection alone (n = 16), (2) C. parvum and a second opportunistic infection (n = 4), and (3) idiopathic AIDS enteropathy with no identified source of infection (n = 3) or an untreatable opportunistic infection other than C. parvum (n = 1). All patients were treated with bovine immunoglobulin concentrate for 21 consecutive days. Patients in cohort 1 were randomized to receive the medication in powder or capsule forms, whereas all patients in cohorts 2 and 3 received the powder form. The primary end point was change in mean daily stool weight. Secondary end points included change in stool frequency and body weight, as well as clearance of C. parvum oocytes as analyzed on stool microscopy. Patients with C. parvum who were treated with bovine immunoglobulin concentrate in powder form experienced a significant decrease in mean stool weight, from 1,158 +/- 114 g/day at baseline, to 595 +/- 63 g/day (p = 0.04) at the end of treatment, and 749 +/- 123 g/day (p = 0.03) 1 month after completing treatment. Stool frequency decreased from 6.6 +/- 0.6 bowel movements per day at study entry, to 5.4 +/- 0.7 during treatment (p = 0.04), and 5.4 +/- 0.9 during observation (p = 0.12). Patients who received bovine immunoglobulin concentrate in capsule form and patients without C. parvum (cohort 3) showed no improvement. No serious side effects were observed, and the medication was well tolerated. Thus, bovine colostrum immunoglobulin concentrate, in powder form, appears promising in the treatment of severe diarrhea caused by C. parvum. The optimal dosage, duration of therapy, and overall efficacy need to be determined in placebo-controlled trials. |
| doi_str_mv | 10.1097/00042560-199612010-00008 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78585358</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>15851152</sourcerecordid><originalsourceid>FETCH-LOGICAL-c420t-925cee25b4b19fd6498e2c5e75e9844ca2f19cb544dd9308648566a55e69b4e43</originalsourceid><addsrcrecordid>eNqFkU1v1DAQhi1U1C6Fn1DJh6q3wPgz9rHa8lGpEgfKOXKcCXWVxKmdLNoTfx3DLnvlNLLf5505PIRQBu8Z2PoDAEiuNFTMWs04MKjKF5hXZMOFYJW2VpyRDYO6rqxUcEHe5PwMwGoh4JycGyuNqMWG_HpM6JYRp4XGnmbcYULaBZfSEzrq3Zqxo-2ebtN-XmKeYwpdWEc6u7Qr42dYnmhMbqBt3IUJaRjHdYo_htiuQ5ioj5Mvu5NbSjSV1hLKMx96t_d3396S170bMr47zkvy_dPHx-2X6uHr5_vt7UPlJYelslx5RK5a2TLbd1pag9wrrBVaI6V3vGfWt0rKrrMCjJZGae2UQm1biVJckpvD3jnFlxXz0owhexwGN2Fcc1MbZZRQ5r8gKxxjihfQHECfYs4J-2ZOYXRp3zBo_khq_klqTpKav5JK9ep4Y21H7E7Fo5WSXx9zl70b-uQmH_IJ44opK7X4DaHHm5w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>15851152</pqid></control><display><type>article</type><title>Treatment of severe diarrhea caused by Cryptosporidium parvum with oral bovine immunoglobulin concentrate in patients with AIDS</title><source>MEDLINE</source><source>Journals@Ovid LWW Legacy Archive</source><source>Journals@Ovid Ovid Autoload</source><creator>GREENBERG, P. D ; CELLO, J. P</creator><creatorcontrib>GREENBERG, P. D ; CELLO, J. P</creatorcontrib><description>We prospectively evaluated the safety and efficacy of colostrum-derived bovine immunoglobulin concentrate in the treatment of diarrhea caused by Cryptosporidium parvum in patients with AIDS. A total of 24 patients with severe chronic diarrhea and AIDS were stratified to one of three cohorts: (1) C. parvum infection alone (n = 16), (2) C. parvum and a second opportunistic infection (n = 4), and (3) idiopathic AIDS enteropathy with no identified source of infection (n = 3) or an untreatable opportunistic infection other than C. parvum (n = 1). All patients were treated with bovine immunoglobulin concentrate for 21 consecutive days. Patients in cohort 1 were randomized to receive the medication in powder or capsule forms, whereas all patients in cohorts 2 and 3 received the powder form. The primary end point was change in mean daily stool weight. Secondary end points included change in stool frequency and body weight, as well as clearance of C. parvum oocytes as analyzed on stool microscopy. Patients with C. parvum who were treated with bovine immunoglobulin concentrate in powder form experienced a significant decrease in mean stool weight, from 1,158 +/- 114 g/day at baseline, to 595 +/- 63 g/day (p = 0.04) at the end of treatment, and 749 +/- 123 g/day (p = 0.03) 1 month after completing treatment. Stool frequency decreased from 6.6 +/- 0.6 bowel movements per day at study entry, to 5.4 +/- 0.7 during treatment (p = 0.04), and 5.4 +/- 0.9 during observation (p = 0.12). Patients who received bovine immunoglobulin concentrate in capsule form and patients without C. parvum (cohort 3) showed no improvement. No serious side effects were observed, and the medication was well tolerated. Thus, bovine colostrum immunoglobulin concentrate, in powder form, appears promising in the treatment of severe diarrhea caused by C. parvum. The optimal dosage, duration of therapy, and overall efficacy need to be determined in placebo-controlled trials.</description><identifier>ISSN: 1077-9450</identifier><identifier>EISSN: 2331-6993</identifier><identifier>DOI: 10.1097/00042560-199612010-00008</identifier><identifier>PMID: 8948373</identifier><language>eng</language><publisher>New York, NY: Raven Press</publisher><subject>Acquired Immunodeficiency Syndrome - complications ; Acquired Immunodeficiency Syndrome - immunology ; Acquired Immunodeficiency Syndrome - parasitology ; Administration, Oral ; Adult ; AIDS/HIV ; Animals ; Biological and medical sciences ; Capsules ; Cattle ; Chronic Disease ; Cohort Studies ; Colostrum - immunology ; Cryptosporidiosis - etiology ; Cryptosporidiosis - therapy ; cryptosporidium parvum ; Cryptosporidium parvum - isolation & purification ; Diarrhea - parasitology ; Diarrhea - therapy ; Feces - parasitology ; Female ; Humans ; Immunization, Passive ; Immunodeficiencies ; Immunodeficiencies. Immunoglobulinopathies ; Immunoglobulins - administration & dosage ; Immunopathology ; Male ; Medical sciences ; Powders ; Prospective Studies</subject><ispartof>Journal of acquired immune deficiency syndromes and human retrovirology, 1996-12, Vol.13 (4), p.348-354</ispartof><rights>1997 INIST-CNRS</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c420t-925cee25b4b19fd6498e2c5e75e9844ca2f19cb544dd9308648566a55e69b4e43</citedby><cites>FETCH-LOGICAL-c420t-925cee25b4b19fd6498e2c5e75e9844ca2f19cb544dd9308648566a55e69b4e43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2515946$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8948373$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>GREENBERG, P. D</creatorcontrib><creatorcontrib>CELLO, J. P</creatorcontrib><title>Treatment of severe diarrhea caused by Cryptosporidium parvum with oral bovine immunoglobulin concentrate in patients with AIDS</title><title>Journal of acquired immune deficiency syndromes and human retrovirology</title><addtitle>J Acquir Immune Defic Syndr Hum Retrovirol</addtitle><description>We prospectively evaluated the safety and efficacy of colostrum-derived bovine immunoglobulin concentrate in the treatment of diarrhea caused by Cryptosporidium parvum in patients with AIDS. A total of 24 patients with severe chronic diarrhea and AIDS were stratified to one of three cohorts: (1) C. parvum infection alone (n = 16), (2) C. parvum and a second opportunistic infection (n = 4), and (3) idiopathic AIDS enteropathy with no identified source of infection (n = 3) or an untreatable opportunistic infection other than C. parvum (n = 1). All patients were treated with bovine immunoglobulin concentrate for 21 consecutive days. Patients in cohort 1 were randomized to receive the medication in powder or capsule forms, whereas all patients in cohorts 2 and 3 received the powder form. The primary end point was change in mean daily stool weight. Secondary end points included change in stool frequency and body weight, as well as clearance of C. parvum oocytes as analyzed on stool microscopy. Patients with C. parvum who were treated with bovine immunoglobulin concentrate in powder form experienced a significant decrease in mean stool weight, from 1,158 +/- 114 g/day at baseline, to 595 +/- 63 g/day (p = 0.04) at the end of treatment, and 749 +/- 123 g/day (p = 0.03) 1 month after completing treatment. Stool frequency decreased from 6.6 +/- 0.6 bowel movements per day at study entry, to 5.4 +/- 0.7 during treatment (p = 0.04), and 5.4 +/- 0.9 during observation (p = 0.12). Patients who received bovine immunoglobulin concentrate in capsule form and patients without C. parvum (cohort 3) showed no improvement. No serious side effects were observed, and the medication was well tolerated. Thus, bovine colostrum immunoglobulin concentrate, in powder form, appears promising in the treatment of severe diarrhea caused by C. parvum. The optimal dosage, duration of therapy, and overall efficacy need to be determined in placebo-controlled trials.</description><subject>Acquired Immunodeficiency Syndrome - complications</subject><subject>Acquired Immunodeficiency Syndrome - immunology</subject><subject>Acquired Immunodeficiency Syndrome - parasitology</subject><subject>Administration, Oral</subject><subject>Adult</subject><subject>AIDS/HIV</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Capsules</subject><subject>Cattle</subject><subject>Chronic Disease</subject><subject>Cohort Studies</subject><subject>Colostrum - immunology</subject><subject>Cryptosporidiosis - etiology</subject><subject>Cryptosporidiosis - therapy</subject><subject>cryptosporidium parvum</subject><subject>Cryptosporidium parvum - isolation & purification</subject><subject>Diarrhea - parasitology</subject><subject>Diarrhea - therapy</subject><subject>Feces - parasitology</subject><subject>Female</subject><subject>Humans</subject><subject>Immunization, Passive</subject><subject>Immunodeficiencies</subject><subject>Immunodeficiencies. Immunoglobulinopathies</subject><subject>Immunoglobulins - administration & dosage</subject><subject>Immunopathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Powders</subject><subject>Prospective Studies</subject><issn>1077-9450</issn><issn>2331-6993</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU1v1DAQhi1U1C6Fn1DJh6q3wPgz9rHa8lGpEgfKOXKcCXWVxKmdLNoTfx3DLnvlNLLf5505PIRQBu8Z2PoDAEiuNFTMWs04MKjKF5hXZMOFYJW2VpyRDYO6rqxUcEHe5PwMwGoh4JycGyuNqMWG_HpM6JYRp4XGnmbcYULaBZfSEzrq3Zqxo-2ebtN-XmKeYwpdWEc6u7Qr42dYnmhMbqBt3IUJaRjHdYo_htiuQ5ioj5Mvu5NbSjSV1hLKMx96t_d3396S170bMr47zkvy_dPHx-2X6uHr5_vt7UPlJYelslx5RK5a2TLbd1pag9wrrBVaI6V3vGfWt0rKrrMCjJZGae2UQm1biVJckpvD3jnFlxXz0owhexwGN2Fcc1MbZZRQ5r8gKxxjihfQHECfYs4J-2ZOYXRp3zBo_khq_klqTpKav5JK9ep4Y21H7E7Fo5WSXx9zl70b-uQmH_IJ44opK7X4DaHHm5w</recordid><startdate>19961201</startdate><enddate>19961201</enddate><creator>GREENBERG, P. D</creator><creator>CELLO, J. P</creator><general>Raven Press</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>H94</scope><scope>M7N</scope><scope>7X8</scope></search><sort><creationdate>19961201</creationdate><title>Treatment of severe diarrhea caused by Cryptosporidium parvum with oral bovine immunoglobulin concentrate in patients with AIDS</title><author>GREENBERG, P. D ; CELLO, J. P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c420t-925cee25b4b19fd6498e2c5e75e9844ca2f19cb544dd9308648566a55e69b4e43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Acquired Immunodeficiency Syndrome - complications</topic><topic>Acquired Immunodeficiency Syndrome - immunology</topic><topic>Acquired Immunodeficiency Syndrome - parasitology</topic><topic>Administration, Oral</topic><topic>Adult</topic><topic>AIDS/HIV</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Capsules</topic><topic>Cattle</topic><topic>Chronic Disease</topic><topic>Cohort Studies</topic><topic>Colostrum - immunology</topic><topic>Cryptosporidiosis - etiology</topic><topic>Cryptosporidiosis - therapy</topic><topic>cryptosporidium parvum</topic><topic>Cryptosporidium parvum - isolation & purification</topic><topic>Diarrhea - parasitology</topic><topic>Diarrhea - therapy</topic><topic>Feces - parasitology</topic><topic>Female</topic><topic>Humans</topic><topic>Immunization, Passive</topic><topic>Immunodeficiencies</topic><topic>Immunodeficiencies. Immunoglobulinopathies</topic><topic>Immunoglobulins - administration & dosage</topic><topic>Immunopathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Powders</topic><topic>Prospective Studies</topic><toplevel>online_resources</toplevel><creatorcontrib>GREENBERG, P. D</creatorcontrib><creatorcontrib>CELLO, J. P</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of acquired immune deficiency syndromes and human retrovirology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>GREENBERG, P. D</au><au>CELLO, J. P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of severe diarrhea caused by Cryptosporidium parvum with oral bovine immunoglobulin concentrate in patients with AIDS</atitle><jtitle>Journal of acquired immune deficiency syndromes and human retrovirology</jtitle><addtitle>J Acquir Immune Defic Syndr Hum Retrovirol</addtitle><date>1996-12-01</date><risdate>1996</risdate><volume>13</volume><issue>4</issue><spage>348</spage><epage>354</epage><pages>348-354</pages><issn>1077-9450</issn><eissn>2331-6993</eissn><abstract>We prospectively evaluated the safety and efficacy of colostrum-derived bovine immunoglobulin concentrate in the treatment of diarrhea caused by Cryptosporidium parvum in patients with AIDS. A total of 24 patients with severe chronic diarrhea and AIDS were stratified to one of three cohorts: (1) C. parvum infection alone (n = 16), (2) C. parvum and a second opportunistic infection (n = 4), and (3) idiopathic AIDS enteropathy with no identified source of infection (n = 3) or an untreatable opportunistic infection other than C. parvum (n = 1). All patients were treated with bovine immunoglobulin concentrate for 21 consecutive days. Patients in cohort 1 were randomized to receive the medication in powder or capsule forms, whereas all patients in cohorts 2 and 3 received the powder form. The primary end point was change in mean daily stool weight. Secondary end points included change in stool frequency and body weight, as well as clearance of C. parvum oocytes as analyzed on stool microscopy. Patients with C. parvum who were treated with bovine immunoglobulin concentrate in powder form experienced a significant decrease in mean stool weight, from 1,158 +/- 114 g/day at baseline, to 595 +/- 63 g/day (p = 0.04) at the end of treatment, and 749 +/- 123 g/day (p = 0.03) 1 month after completing treatment. Stool frequency decreased from 6.6 +/- 0.6 bowel movements per day at study entry, to 5.4 +/- 0.7 during treatment (p = 0.04), and 5.4 +/- 0.9 during observation (p = 0.12). Patients who received bovine immunoglobulin concentrate in capsule form and patients without C. parvum (cohort 3) showed no improvement. No serious side effects were observed, and the medication was well tolerated. Thus, bovine colostrum immunoglobulin concentrate, in powder form, appears promising in the treatment of severe diarrhea caused by C. parvum. The optimal dosage, duration of therapy, and overall efficacy need to be determined in placebo-controlled trials.</abstract><cop>New York, NY</cop><pub>Raven Press</pub><pmid>8948373</pmid><doi>10.1097/00042560-199612010-00008</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1077-9450 |
| ispartof | Journal of acquired immune deficiency syndromes and human retrovirology, 1996-12, Vol.13 (4), p.348-354 |
| issn | 1077-9450 2331-6993 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78585358 |
| source | MEDLINE; Journals@Ovid LWW Legacy Archive; Journals@Ovid Ovid Autoload |
| subjects | Acquired Immunodeficiency Syndrome - complications Acquired Immunodeficiency Syndrome - immunology Acquired Immunodeficiency Syndrome - parasitology Administration, Oral Adult AIDS/HIV Animals Biological and medical sciences Capsules Cattle Chronic Disease Cohort Studies Colostrum - immunology Cryptosporidiosis - etiology Cryptosporidiosis - therapy cryptosporidium parvum Cryptosporidium parvum - isolation & purification Diarrhea - parasitology Diarrhea - therapy Feces - parasitology Female Humans Immunization, Passive Immunodeficiencies Immunodeficiencies. Immunoglobulinopathies Immunoglobulins - administration & dosage Immunopathology Male Medical sciences Powders Prospective Studies |
| title | Treatment of severe diarrhea caused by Cryptosporidium parvum with oral bovine immunoglobulin concentrate in patients with AIDS |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T18%3A30%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20severe%20diarrhea%20caused%20by%20Cryptosporidium%20parvum%20with%20oral%20bovine%20immunoglobulin%20concentrate%20in%20patients%20with%20AIDS&rft.jtitle=Journal%20of%20acquired%20immune%20deficiency%20syndromes%20and%20human%20retrovirology&rft.au=GREENBERG,%20P.%20D&rft.date=1996-12-01&rft.volume=13&rft.issue=4&rft.spage=348&rft.epage=354&rft.pages=348-354&rft.issn=1077-9450&rft.eissn=2331-6993&rft_id=info:doi/10.1097/00042560-199612010-00008&rft_dat=%3Cproquest_cross%3E15851152%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=15851152&rft_id=info:pmid/8948373&rfr_iscdi=true |